Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Adding everolimus to endocrine therapy in patients with HER2- ER+ advanced breast cancer

Posted by on Jan 5, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if treating breast cancer with everolimus (Afintor) and endocrine therapy is better than only treating with endocrine therapy. The study found that using everolimus in addition to endocrine therapy had a significant benefit to survival in these patients. Some background Breast cancer is classified into types...

Read More

Adding ixabepilone to capecitabine treatment for triple negative breast cancer.

Posted by on Dec 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if ixabepilone (Ixempra) and capecitabine (Xeloda) work for treating triple-negative breast cancer in patients with hard to treat disease compared to using capecitabine alone. The study found that adding ixabepilone to treatment resulted in longer survival without the cancer progressing. Some background...

Read More

Treating non-small cell lung cancers that have spread.

Posted by on Dec 11, 2018 in Lung cancer | 0 comments

In a nutshell This paper is about how to diagnose, treat, and follow up on non-small cell lung cancer cases that have spread through the body. The paper overall noted that non-small cell lung cancer which has spread is often very aggressive and hard to treat, and that methods of treatment are still being developed.   Some background Non-small...

Read More

Erlotinib in patients with non-small cell lung cancer

Posted by on Dec 11, 2018 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using the medication erlotinib (Tarceva) in patients with non-small cell lung cancer improved survival. The study found that using erlotinib was safe, and may reduce the need for radical surgery in patients with non-small cell lung cancer. Some background Epidermal growth factor receptor (EGFR) is...

Read More

Can white blood-cell levels predict tumor response in rectal cancer?

Posted by on Nov 20, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated if a change in white blood cell (WBC) levels before or during chemotherapy and radiation therapy are associated with rectal tumor response. Researchers suggested that a decreased level of WBC is associated with improved tumor response in patients with rectal cancer. Some background Chemotherapy and radiation...

Read More

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Posted by on Nov 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane).  The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...

Read More

Metronomic chemotherapy for HR+ advanced breast cancer

Posted by on Nov 7, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well using metronomic chemotherapy with capecitabine (Xeloda) combined with aromatase inhibitors works for patients with hormone receptor positive advanced breast cancer. The study found that this treatment works well and is safe, and therefore should be considered as a potential treatment option. Some...

Read More

Treatment for advanced melanoma with abnormal genes

Posted by on Nov 4, 2018 in Melanoma | 0 comments

In a nutshell This study wanted to find out which treatment for melanoma cancer worked better, encorafenib (Braftovi) + binimetinib (Mektovi), encorafenib alone, or vemurafenib (Zelboraf) alone. The study found that encorafenib + binimetinib worked well and was safe, compared to vemurafenib and encorafenib. Some background In about 50% of patients...

Read More

Palbociclib and Fulvestrant in Advanced Breast Cancer.

Posted by on Nov 3, 2018 in Breast cancer | 0 comments

In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...

Read More